HR Execs on the Move

Mixhers

www.mixhers.com

 
Mixhers is a company that provides supplements designed specifically for womens health and wellness, with each product carefully crafted to support women in all stages of life.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Amanda Rasmussen
Director of Supply Chain and Logistics Profile
Britnee Nuehring
Chief Sales Marketing Officer Profile

Similar Companies

Canvas Health

Dedicated to bringing hope, healing and recovery to children, adolescents, adults and families struggling with mental health, chemical health and abuse.

Civica Rx

Civica Rx was created in late 2018 to secure the supply of important medicines hospitals use every day. As of Q2 2023, we have provided over 125 million units of essential medicines to hospitals, enough to help treat over 50 million patients. Recently, we announced we will manufacture and distribute affordable medications for consumers in an outpatient/retail setting, including affordable insulin. Insulin is an exciting project as we are partnering with nearly every corner of the diabetes ecosystem to bring low-cost insulin to people living with diabetes at no more than $30 a vial and no more than $55 for a pack of five pre-filled pens, regardless of insurance status.

Avanti Therapeutics

Avanti Therapeutics is a Clarksburg, MD-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Forma Therapeutics

At FORMA, patients are our purpose. We are dedicated to delivering transformative medicines to patients with cancer and rare diseases. We are a fully-integrated, privately-held clinical stage biopharmaceutical company. A leader in metabolism, epigenetics and protein homeostasis focused on the discovery, development and commercialization of transformative medicines. Our proprietary R&D platform combines deep biology insight, chemistry expertise and clinical development capabilities to create differentiated drug candidates. We have delivered high-value clinical candidates to our partners and generated a broad proprietary portfolio of internal programs, ranging from pre-clinical to pivotal-stage, with the potential to provide profound patient benefit in hematologic, oncologic and metabolic indications.